Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Pluri Inc. (PLUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.52% for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-05-14
- Pluri Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 3.25%.
- Pluri Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 1.08%, a 0.00% change from fiscal 2023.
- Pluri Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 1.08%, a 0.00% change from fiscal 2022.
- Pluri Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.08%, a 575.00% increase from fiscal 2021.
- Pluri Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.16%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-03-31 | 3.52% 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 3.52% 10-Q · filed 2026-02-12 | |||
| 2024-06-30 | 1.08% 10-K · filed 2024-09-18 | |||
| 2023-06-30 | 1.08% 10-K · filed 2023-09-12 | |||
| 2023-03-31 | 3.25% 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 3.25% 10-Q · filed 2023-02-13 | |||
| 2022-09-30 | 3.25% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 1.08% 10-K · filed 2022-09-21 | |||
| 2022-03-31 | 1.08% 10-Q · filed 2022-05-09 | |||
| 2021-06-30 | 0.16% 10-K · filed 2021-09-13 | |||
| 2021-03-31 | 0.16% 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |